Ursodeoxycholic Acid Reduces Angiotensin‐Converting Enzyme 2 Activity and Suppresses Cytokine Storm Syndrome in Patients With Coronavirus Disease 2019
Zhaowei Tong, Jiawei Zhu, Jianfeng Zhong, Qi Wang, Fuchu Qian, Lili Zhao, Weihong Wang, Yuepao Cai, Kefeng Qin · 2026
Read Ursodeoxycholic Acid Reduces Angiotensin‐Converting Enzyme 2 Activity and Suppresses Cytokine Storm Syndrome in Patients With Coronavirus Disease 2019 by Zhaowei Tong, Jiawei Zhu, Jianfeng Zhong, Qi Wang, Fuchu Qian, Lili Zhao, Weihong Wang, Yuepao Cai, Kefeng Qin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13527531.txt.
Description
Zhaowei Tong and eight colleagues test whether the liver drug ursodeoxycholic acid can blunt COVID-19 by lowering the ACE2 entry receptor. The drug inhibits a receptor that controls ACE2 levels. In their study, 142 patients received standard antivirals, and eighty-nine also took the bile acid drug for ten days.
ACE2 levels in blood and its gene expression in blood cells fell faster in the treated group. In cell culture the drug reduced ACE2 and blocked infection by a pseudovirus carrying a recent spike variant. Twenty-one inflammatory cytokines were significantly lower with treatment, consistent with calming the cytokine storm. The authors report improved clinical outcomes and propose the drug as an adjunct antiviral strategy.
Catalog record
| CREATOR | Zhaowei Tong, Jiawei Zhu, Jianfeng Zhong, Qi Wang, Fuchu Qian, Lili Zhao, Weihong Wang, Yuepao Cai, Kefeng Qin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |